🇧🇷Brazil

Perda de Capacidade Operacional e Desperdício de Investimento em Sistemas de Prescrição

2 verified sources

Definition

Pharmacies implementing CFF Resolution 5/2025 invested in prescription verification software, Drug Utilization Review (DUR) modules, and staff certification. Federal court suspension on March 31, 2025 renders these systems non-compliant. Stranded capital in form of software licenses, hardware, and certified staff hours.

Key Findings

  • Financial Impact: Estimated R$ 100,000-500,000 per pharmacy network in sunk IT/software costs. Plus 40-80 hours/month of staff capacity previously allocated to prescription verification now unproductive.
  • Frequency: Permanent capacity loss until alternative revenue models identified or court decision overturned.
  • Root Cause: Pharmacies made capital expenditure decisions based on CFF Resolution 5/2025 without scenario planning for judicial reversal. Federal Court determined resolution exceeded CFF authority under Law 12.842/2013.

Why This Matters

The Pitch: Retail pharmacies in Brasil 🇧🇷 wasted R$ 500K-2M+ on prescription verification systems and staff training for a capability now legally prohibited. Redeployment audit identifies cost recovery and alternative revenue streams.

Affected Stakeholders

IT/systems managers, Prescription verification technicians, Clinical pharmacists (prescription review staff), Finance (capital budgeting)

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Multa por Violação de Competência Profissional e Risco de Revogação de Alvarás

Estimated R$ 50,000-200,000 per pharmacy location in compliance remediation, system reversion, and staff retraining. Plus exposure to administrative fines (Lei 6.437/77) for operating without proper competency authorization.

Perda de Receita por Serviços de Prescrição Farmacêutica Agora Proibidos

Estimated R$ 5,000-25,000/month per pharmacy location in lost prescription consultation revenue. Annual impact: R$ 60,000-300,000 per location for pharmacy networks.

Erros de Decisão Estratégica Baseados em Regulação Revogada

Estimated R$ 200,000-1,000,000 per pharmacy network in erroneous hiring, system contracts, and service buildout tied to prescription authorization now suspended.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Penalidades por Não-Conformidade ao SNGPC (Portaria 344/1998)

LOGIC-based estimate: Typical ANVISA administrative fines for non-compliance range R$ 5,000–R$ 50,000 per violation; larger networks face R$ 100,000+ for systemic SNGPC failures. Operational costs from license suspensions or revocation: loss of controlled-substance revenue (15–30% of pharmacy revenue), estimated R$ 50,000–R$ 500,000+ per pharmacy per month during suspension.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence